Costs of PCSK9 inhibitors may be prohibitive
With the pending approval of two cholesterol-lowering drugs, the Washington Post reports concerns are mounting about the costs of the medications, which are both injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
The FDA is expected to approve alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) by July 24. The other PCSK9 inhibitor, evolocumab (Repatha, Amgen), is expected to be approved by Aug. 27. In June, FDA advisory committees recommended approval of both drugs. For more, check out the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.